ILMN · Illumina, Inc.

The thesis

Illumina's clinical sequencing recovery is still the case, but the shares have kept falling since the 6 October 2026 reversal and now wait on one report. The third-quarter fiscal 2026 results, which Illumina has confirmed for after the close on 29 October 2026, must beat the $1.14–$1.16 billion revenue outlook to restart the advance. Until then the business evidence is stronger than the price action.

The shares closed at $264.57 on 8 October 2026 in adjusted daily closes. That is 9.9% below the $293.69 52-week closing high of 5 October 2026 and below the 6 October 2026 close of $273.54. Over three months the shares are still up 39.2%, and the 14-day relative strength index stood at 61.5 on 8 October 2026.

The narrative is saturated: the clinical recovery argument has been repeated in five broker target increases since 9 September 2026, buyers did not hold the price once it reached RBC Capital's $310 target on 6 October 2026, and Barclays kept its Underweight rating on 7 October 2026 even while raising its target to $200. New buyers from the 21 September 2026 S&P 500 rejoin have already arrived. Fresh demand now has to come from reported numbers.

Bullish and bearish views on Illumina, Inc.

The bull case on Illumina, Inc. (ILMN), in brief: Second quarter raised the annual bar. The bear case: The rally failed at the top target.

Bull case

• Second quarter raised the annual bar. Illumina reported Q2 fiscal 2026 revenue of $1.159 billion on 30 July 2026 and raised full-year revenue guidance to $4.60–$4.64 billion (Form 8-K).
• Clinical consumables carry the growth. On the 30 July 2026 call, management reported Q2 clinical consumables growth of 15% year over year excluding China and more than 95 NovaSeq X placements. Management guides six to nine months from placement to normal consumables usage, so first-half placements should reach second-half revenue.
• Four brokers raised targets in eight days. Piper Sandler moved to $305 from $225 on 28 September 2026, Leerink Partners to $300 from $220 on 29 September 2026, Guggenheim to $305 from $226 on 1 October 2026 and RBC Capital to $310 from $230 on 5 October 2026, according to Benzinga. RBC cited a clinical sales inflection and oncology-driven test volume.
• The report date is now fixed. Illumina has announced it will release Q3 results after the market close on Thursday, 29 October 2026, with a call at 1:30 p.m. Pacific time hosted by CEO Jacob Thaysen and CFO Ankur Dhingra (Illumina investor relations).
• Index membership widened ownership. Illumina rejoined the S&P 500 before the open on 21 September 2026. Benzinga put market capitalisation at $37.84 billion on 22 September 2026, up from $34.28 billion on 16 September 2026.

Bear case

• The rally failed at the top target. On 6 October 2026 the shares opened at $301.58, touched $309.35 and fell to an intraday low of $272.35 while the S&P 500 and Nasdaq traded higher, according to Investing.com. The 8 October 2026 close of $264.57 sits below that intraday low.
• A bear stays bearish after the rally. Barclays maintained Underweight on 7 October 2026 and raised its target to $200, according to Benzinga. That target sits well under the 8 October 2026 close, as does UBS's $260 target from its 9 September 2026 upgrade.
• Valuation runs ahead of consensus. Investing.com put the shares at about 52 times earnings on 6 October 2026, with a consensus rating of hold.
• Insiders have sold into the rise. SEC Form 4 filings show director Keith Meister reported open-market sales of 263,560 shares by Corvex funds from 2 September to 4 September 2026 at weighted averages of $213.20 to $221.55. Investing.com put total insider selling at more than $436 million in recent months, with no open-market purchases.
• Profitability lagged revenue in Q2. Q2 fiscal 2026 operating cash flow was $201 million against $234 million a year earlier, and adjusted operating margin was 22.5% against 23.8%, per the 30 July 2026 release.

Price setup

The 52-week closing high is $293.69, set on 5 October 2026 after RBC's target increase lifted the shares 7.85% that day. The 6 October 2026 session produced the intraday high of $309.35 and an intraday low of $272.35. The shares closed at $273.54 that day and at $264.57 on 8 October 2026.

Two reference prices sit close beneath the last close. UBS's $260 target from 9 September 2026 is the nearest analyst level. Below it, the early-September range where Corvex funds sold, $213.20 to $221.55 per Form 4 filings, marks where the late-September advance began.

Crowding is visible in three places: a 39.2% three-month gain, more than $436 million of reported insider selling, and an earnings date 21 days after the last close. A 61.5 relative strength reading on 8 October 2026 shows the momentum has cooled from the early-October high without reversing outright.

Catalysts, next 30 days

• 29 October 2026 — Q3 fiscal 2026 results, after the close; call at 1:30 p.m. Pacific time. The report tests the $1.14–$1.16 billion quarterly revenue outlook, clinical consumables growth excluding China and the $4.60–$4.64 billion annual range. MarketBeat listed Q3 consensus earnings per share at $1.41 as of 5 October 2026.

What would change the view

The operating case breaks if Q3 fiscal 2026 revenue comes in below the $1.14 billion floor of the 30 July 2026 outlook, or if management lowers the $4.60–$4.64 billion full-year range on 29 October 2026. Either would show the clinical recovery that brokers priced in during late September has not reached reported sales.

On price, a daily close below $260 would put the shares at UBS's 9 September 2026 target and extend the slide that began with the 6 October 2026 reversal.

The case would strengthen if Q3 revenue lands above $1.16 billion with clinical consumables growth excluding China at or above the 15% of Q2, and if adjusted operating margin and operating cash flow return above year-earlier levels. A close back above the $293.69 52-week high would show buyers absorbing the insider supply.

What it trades with

Illumina now trades inside the S&P 500, so index flows touch it alongside the rest of the benchmark. Its own drop on 6 October 2026, while both the S&P 500 and Nasdaq rose, shows the stock still moves on company-specific news.

A 52-times earnings multiple makes the shares sensitive to interest rates. Benzinga reported the 10-year Treasury yield topped 5% on 15 September 2026 for the first time since 2007, and a further rise would weigh on high-multiple diagnostics names together.

Among diagnostics peers, Grail (GRAL) shares the cancer-screening end market, and RBC initiated Grail on 18 September 2026 at Sector Perform with an $84 target ahead of an FDA advisory panel. Peer reports from sequencing-heavy testing companies such as Natera (NTRA) in late October offer a read on clinical test volumes before or alongside Illumina's own report.